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Abstract 
Background and Objective: Glanzmann thrombasthenia (GT) is an autosomal 
recessive bleeding disorder characterized by a life-long hemorrhagic tendency and 
absence or severely reduced platelet aggregation in response to agonists, and caused 
by quantitative or qualitative abnormalities in the platelet fibrinogen receptor, integrin 
αIIbβ3. The aim of this study was to identify the molecular genetic defect and 
determine its functional consequences in a patient with type II GT. 
Design and Methods: The expression of platelet αIIbβ3 was determined by flow 
cytometry and western blot. Identification of mutations was carried out by sequencing 
both cDNA and genomic DNA. Functional characterization was assessed by exontrap 
and transient transfection analysis. 
Results: Flow cytometry and western blot analysis revealed markedly reduced levels 
of platelet αIIbβ3, that may account for the residual fibrinogen binding detected upon 
platelet activation. Sequencing of genomic DNA revealed the presence of two 
mutations in the αIIb gene: a C1750T transition in the last codon of exon 17 changing 
Arg553 to STOP, and a C2829T transition in exon 27 that changes Pro912 to Leu. 
Sequence analysis of reversely transcribed αIIb mRNA did not detect cDNA from the 
C1750T mutant allele, and revealed a significant increase of the physiological splicing 
out of exon 28 in the cDNA carrying the C2829T mutation. Transient expression of 
[912Leu]αIIb in CHO-β3 cells showed a markedly reduction in the rate of surface 
expression of αIIbβ3. 
Interpretation and conclusions: The results suggest that the thrombasthenic phenotype 
is the result of reduced availability of αIIb-mRNA, enhanced expression of exon 28-
deleted transcripts, and defective processing of [912Leu]αIIb. 
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Introduction 
Glanzmann thrombasthenia (GT) is an autosomal recessive bleeding disorder 
characterized by a life-long hemorrhagic tendency and absence or severely reduced 
platelet aggregation in response to agonists (1,2). The thrombasthenic phenotype is 
associated with quantitative or qualitative abnormalities in the platelet fibrinogen 
receptor, the αIIbβ3 integrin or glycoprotein (GP) IIb-IIIa, which can also serve as 
platelet receptor for fibronectin, vitronectin and von Willebrand factor (3-5). 
Heterozygous individuals, with 50-60% the normal amount of platelet αIIbβ3, have 
no abnormalities of platelet function and are clinically asymptomatic. The degree of 
platelet content of αIIbβ3 is used to categorize the disease into three types (1): type I, 
with total absence of platelet αIIbβ3; type II, with < 20% of normal platelet content; 
and variant GT, with near normal amount of αIIbβ3. A number of mutations, 
worldwide distributed, have been found associated to GT (6,7) including minor or 
major deletions, insertions, inversions and mostly point mutations. The functional 
characterization of many of them has provided important information on the 
assembly, stability and intracellular transport of the complex (2). 
Most of the reported single nucleotide substitutions are located in the coding 
sequence, and they cause missense or nonsense substitutions at the amino acid level, 
producing either normal-sized non-functional or truncated proteins (6-9). Mutations 
that alter mRNA splicing are frequently nonsense mutations (10, 11) or mutations 
directly affecting the standard consensus splicing signals (12), and typically lead to 
skipping of the neighboring exon. Less commonly, exonic splicing mutations are 
missense or even silent mutations that generate an ectopic site (13) that is used 
preferentially, or activate a cryptic splice site (14). 
In nonsense-associated altered splicing (NAS), deletion of exons with premature 
termination codons appears to be mediated, at least in part, by a mechanism in which 
recognition of the translational reading-frame is involved (15,16). Exon skipping is 
also found associated to an increasing number of point mutations other than those of 
the nonsense type. Mechanisms involving alteration of pre-mRNA secondary 
structure and disruption or creation of cis-acting exonic signals, such as exonic 
splicing enhancers (ESE) and silencers (ESS), have been proposed to explain exon 
skipping resulting from missense and silent mutations (15). 
The production of different isoforms from the same transcription unit is very 
common in mammalian cells. Alternative splicing forms of the β3 and αIIb integrin 
subunits have been identified during screening of cDNA libraries and the cellular 
transcripts detected by RT-PCR (17,18). The alternatively spliced form of αIIb results 
from in-frame deletion of a 102 bp of exon 28 (18). As reported for other genes (19), 
inherent weak splicing signals for exon 28 may account for its constitutional deletion. 
The low expression of the deleted transcript and the failure of αIIb-28 protein to reach 
the cell surface suggest that it has not a significant biological function. 
We characterize here the genetic defect in a case of type II GT caused by 
compound heterozygosis of the αIIb gene due to nonsense C1750T and missense 
C2829T mutations. The nonsense mutation changes Arg to STOP in the last codon of 
exon 17 and the aberrant mRNA is not detectable in our experimental conditions of 
PCR amplification. The C2829T transition changes Pro912 to Leu in the mature αIIb 
peptide and, unexpectedly, results in increase of skipping of the contiguous exon 28. 
Therefore, the thrombasthenic phenotype of the proband is associated to a limited 
availability of αIIb-mRNA, enhanced expression of exon 28-deleted transcripts, and 
altered processing of [912Leu]αIIb protein. 
4 
Design and Methods 
Antibodies 
Murine monoclonal antibodies (mAb) specific for β3 (H1AG11) and αIIb (2BC1) 
were raised in our laboratory using as antigen αIIbβ3 heterodimer isolated from 
human platelets (20). The anti-αvβ3 mAb LM609 was from Chemicon (Temecula, 
CA, USA). mAb AK2 (anti-GPIbα) was from Serotec (Oxford, UK), and SZ1 (anti-
GPIX) was from Beckman Coulter (Fullerton, CA, USA). Fluorescein isothiocyanate-
conjugated (FITC) F(ab’)2 fragment of rabbit anti-mouse immunoglobulin (Ig) was 
purchased from Dako A/S (Denmarck). The horseradish peroxidase (HRP)-
conjugated goat anti-mouse was from Bio-Rad Laboratories (Hercules, CA, USA). 
 
Case report 
The patient is a 2-year-old female from China with clinical diagnosis of 
Glanzmann thrombasthenia (GT), with frequent epistaxis and mucocutaneous 
hemorrhages that started immediately after birth. The patient showed prolonged 
bleeding time and platelets of normal size and number. Platelet aggregation in 
response to ADP, collagen, adrenaline and arachidonic acid was less than 5% of 
control platelets and no clot retraction was observed. Ristocetin-induced platelet 
agglutination and plasma fibrinogen content were within the normal range. No 
information about family antecedents was available since the child was adopted. 
 
Flow cytometry analysis of platelets surface receptors 
Platelet-rich-plasma (PRP) was obtained from venous whole blood by 
centrifugation at 150 g for 20 min at room temperature. Platelets were sedimented at 
1,000 g for 10 min, washed with 0.5 mM EDTA in phosphate-buffered saline (PBS), 
and incubated, at a concentration of 106 cells/100 µl, with the specific mAb for 30 
min. After washing, the platelets were incubated in a 1:25 dilution of fluorescein 
isothiocyanate (FITC)-conjugated F(ab’)2 fragment of rabbit anti-mouse Ig for 20 
min. Samples were analysed in a Coulter flow cytometer, model EPICS XL. 
 
Binding of fibrinogen to activated platelets 
FITC-labeled human fibrinogen (Fg) was prepared as previously described (13). 
The PRP was diluted with Hepes/citrate buffer, pH 7.4 (5 mM Hepes, 2 mM MgCl2, 
0.3 mM NaH2PO4, 3 mM KCl, 134 mM NaCl, 12 mM NaHCO3, 12.9 mM Na citrate, 
0,1% glucose, 0,1% bovine serum albumin and 1 mM Cl2Ca) to a final concentration 
of 5 x 107 platelets/ml. Platelets (60 µl) were activated for 5 min at room temperature 
with one or more of the following activating agents: 1 mM dithiothreitol (DTT) (BRL, 
Life Technologies, Co.), 50 µM adenosine 5’-diphosphate (ADP) (Sigma), 1 mM 
epinephrine (Sigma). Then, 7.5 µg of FITC-Fg was added and, after 15 min at room 
temperature, platelets were washed and resuspended in Hepes/citrate buffer for flow 
cytometry analysis. 
 
Total platelet content of platelet αIIb, β3 and αvβ3 
Platelet proteins were solubilized in lysis buffer (50 mM Tris, pH 7.4, 150 mM 
NaCl, 1% Triton X-100, 0.05% Tween 20) supplemented with 1 mM phenylmethyl 
sulfonyl fluoride (PMSF) and 5 µl/100 µl protease inhibitor cocktail (Sigma). After 
20 min on ice, lysates were cleared by centrifugation and resolved on sodium dodecyl 
sulfate (SDS)-7.5% polyacrylamide gels under non-reduced conditions, transferred to 
PVDF membranes and, then, incubated with mixed mAbs against αIIb and β3. The 
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specific bound antibodies were detected with a peroxidase-conjugated goat anti-
mouse IgG and visualized using the ECL chemiluminescent system. Quantification of 
the western blots was performed by densitometry scanning of the autoradiographs. 
To determine the platelet content of αvβ3, 300 µg of solubilized platelet protein 
were pre-cleared and immunoprecipitated for four hours at 4ºC with 1.5 µg of anti-
αvβ3 mAb. The immunoprecititates were treated for two hours with protein A-
sepharose CL-4B (Amershan Biosciences), washed and eluted by boiling 10 min in 25 
µl of non-reduced loading buffer, and analyzed by western blotting with the anti-β3 
mAb as described above. 
 
Sequence analysis of reversed transcribed mRNAs and genomic DNA fragments 
of αIIb and β3  
Total platelet RNA was obtained by the guanidinium isothiocyanate procedure. 
Screening for mutations was carried out by direct sequencing of PCR amplified 
overlapping fragments of reversed transcribed αIIb and β3 mRNAs. The 
oligonucleotide pair used for amplification and sequencing of the 3’ fragment of αIIb-
cDNA have been previously reported (14). 
Genomic DNA was isolated from peripheral blood cells. Amplification of DNA 
was carried out with Taq polymerase using oligonucleotides from intronic flanking 
regions. A 890-bp DNA fragment encompassing exons 27 to 29 was amplified using 
the oligonucleotide pair: sense-intron 26: 5’-atgatggggtgatgggccgga-3’, and antisense-
intron 29: 5’-aacctgggtgtgtgcaactct-3’, The 1468-bp DNA fragment containing exons 
13 to 18 was amplified using the oligonucleotide pair: sense-intron 12: 5’-
aataacaatcagccacttcct-3’, and antisense-intron 18: 5’-acttggcactaaccctaatcc-3’. Direct 
DNA sequencing was performed in an automatic Applied Biosystems sequencer.  
 
Exontrap analysis 
The exontrap vector system (Mo Bi Tec GmbH, Göttingen, FRG) was used to 
analyze whether the C2829T mutation in exon 27 alters the splicing pattern of the 
mutant transcript. Genomic DNA from a control and the patient were used for PCR-
amplification of a 890-bp DNA fragment encompassing exons 27-29 and the adjacent 
regions of introns 26 and 29, as described above. The PCR products were subcloned 
and cloned into Xho I-Bam HI digested exontrap vector. Sequence analysis was 
performed to verify the correct insertion and absence of errors potentially caused by 
the Taq polymerase. The constructs with the normal or mutant αIIb sequence were 
transiently transfected into CHO cells using Lipofectamine reagent (Invitrogen) and, 
48 hours after transfection, total RNA was extracted and RT-PCR was performed as 
previously described (10). 
 
Transient expression of wild and mutant αIIb 
Expression plasmid containing mutant αIIb-cDNA was prepared as followed. Total 
RNA from the patient was used for RT-PCR amplification of a 1114 bp fragment of 
αIIb-cDNA, using the oligonucleotides sense (1995-2015) and antisense (3129-3109), 
as described above. The PCR product was digested and ligated into the Apa I- and 
HinD III- digested pcDNA3.1(-)/Myc-His B vector (Invitrogen, San Diego, CA) 
containing the wild-type αIIb-cDNA, that was previously treated to disrupt Apa I site 
in polylinker. To generate wild and mutant expression plasmids containing the “b” 
allelic form of the HPA-3 (Ile843Ser) polymorphism, a BamH I cDNA fragment from 
the patient was exchanged for the corresponding segment in wild and mutant vectors. 
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Nucleotide sequence was performed to verify the correct orientation of the cloned 
fragments. 
CHO cells stably expressing β3 (CHO-β3) were grown in Dulbecco's modified 
Eagle medium (DMEM) supplemented with 10% fetal calf serum. Cells were 
transiently transfected by the diethyl aminoethyl (DEAE)-dextran method with 15 µg 
of either normal or mutated αIIb constructs. 48 hours after transfection the cells were 
harvested and the surface expression of αIIbβ3 complexes was determined by flow 
cytometry analysis. 
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Results 
The patient is a two year-old female from China whose history of bleeding 
episodes started immediately after birth. The clinical diagnosis of Glanzmann 
thrombasthenia (GT) was based on prolonged bleeding time, normal platelet count, 
and absence of spontaneous or agonist-induced platelet aggregation. 
The platelet content of αIIbβ3 was estimated by flow cytometry and western blot 
analysis. As shown in Fig. 1A, platelets from the patient incubated with antibodies 
against αIIb and β3 subunits showed detectable positive fluorescence relative to the 
signal obtained by incubating cells only with the second fluorescent anti-mouse IgG, 
but the mean fluorescence intensities account for less than 10% of surface expression 
of αIIbβ3 relative to control platelets. The analysis also revealed a normal surface 
content of the platelet GPIb-IX complex. Quantitation of platelet αIIbβ3 by western 
blot analysis (Fig. 2) showed results consistent with those of flow cytometry. The 
platelet content of αvβ3 was estimated by immunoprecipitation analysis using the 
mAb LM609 that recognizes a site on the αvβ3 vitronectin receptor present when αv 
and β3 are complexed together. As shown in Fig. 2, similar amounts of the complex 
were detected in the patient and the control when the immunoprecipitated proteins 
were blotted with an anti-β3 mAb. 
The capacity of the GT platelets to bind soluble Fg was assessed by incubation in 
the absence or presence of different activators, and the binding of FITC-Fg was 
estimated by flow cytometry analysis. As shown in Fig.1, in response to the 
stimulation with agonists, a percent of the platelets from the patient exhibited a 
detectable increase in surface fluorescence. However, the values of fluorescence, 
calculated as a product of the percent of gated positive cells and the values of mean 
channel of fluorescence, in the activated platelet population from the patient was 
approximately 10-fold lower than in the control. DTT stimulated the binding of 
control platelets to Fg, but no effect was observed on platelets from the proband. 
 
Identification of mutations in the αIIb gene 
The normal amount of platelet αvβ3 in the patient suggested that the reduced 
levels of αIIbβ3 complex were not due to a limited availability of β3. Thus, we first 
searched for mutations in the αIIb gene by sequencing PCR-amplified overlapping 
fragments of reversed transcribed αIIb-mRNA. This analysis revealed a homozygous 
single C2829T substitution in exon 27 that would result in the change of Pro to Leu at 
position 912 in the mature αIIb peptide (Fig. 3). The analysis also showed 
homozygosis for the HPA-3 polymorphism that results from a T to G mutation in 
exon 26 changing Ile843 to Ser. 
Since the presence of the mutation could not be evaluated in the biological parents 
we estimated necessary to verify the homozygous status by analyzing the genomic 
DNA. Sequence analysis of a DNA fragment encompassing exons 27-29 
demonstrated that the proband was heterozygous for the C2829T transition (Fig. 3), 
suggesting the presence of another αIIb mutation that would result in absent or very 
limited amounts of mRNA since no transcripts were detected in the RT-PCR analysis. 
Thus, we analyzed the coding and partial intronic sequences of αIIb by sequencing 
PCR products encompassing one or more exons. This analysis demonstrated the 
presence of a heterozygous C1750T transition in the last codon of exon 17 that 
changes residue Arg553 to STOP codon. The resulting aberrant transcript is predicted 
to encode a severely truncated αIIb subunit consisting of only 552 amino acids, 456 
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residues shorter than the normal protein, lacking the transmembrane and cytoplasmic 
domains. 
These mutations were not found in a significant number of DNAs from normal 
healthy donors. Moreover, no other mutations were identified in the propositus after 
complete analysis of β3 and αIIb coding sequences. 
 
Exontrap analysis of normal and mutant αIIb alleles 
αIIb mRNA with deleted exon 28 (αIIb-28) is a rare alternatively spliced product 
found in normal platelets. However, a significantly increased number of deleted forms 
of the transcript, was observed in the patient when the DNA sequence of individual 
clones was analyzed (data no shown). To determine whether the C2829T transition is 
inducing skipping of exon 28 we analyzed the splicing of this portion of the αIIb gene 
transfected into CHO cells, using the exontrap vector system. Fig. 4A schematically 
displays the minigene constructs used in these experiments. We examined the αIIb 
transcripts generated from the normal and mutant alleles by RT-PCR. The construct 
containing the wild sequence yielded products of similar intensity of approximately 
400 and 300 bp. However, a near 100% relative increase of the 300 bp product, as 
quantified by densitometry scanning, was observed in the RT-PCR analysis of cells 
transfected with the mutant C2829T construct (Fig. 4). Sequence analysis revealed 
that the amplified products correspond to normal and exon 28 deleted forms of the 
αIIb transcript, respectively. 
 
Transient expression of mutant forms of αIIb in CHO-β3 cells 
Fig. 5 depicts the results obtained by expressing either normal [912P]αIIb or 
mutant [912L]αIIb into CHO cells that stably express β3 on the cell surface 
associated with endogenous α subunits (CHO-β3 cells). In view of the simultaneous 
presence and close proximity of the mutated residue and the HPA-3b polymorphism 
(843Ser), we also analyzed the effect of transfecting αIIb-cDNA containing both 
substitutions. The rate of surface exposure of αIIbβ3 complexes was similar in cells 
transfected with either normal or polymorphic αIIb-cDNA. However, the P912L 
substitution markedly decreased the expression of αIIbβ3 complexes at the cell 
surface in the presence of both forms of the HPA-3 polymorphism. 
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Discussion 
The present work aimed at investigating the molecular basis of the bleeding 
disorder presented by a patient with clinical phenotype of Glanzmann thrombasthenia 
(GT). The platelet content of αIIbβ3, assessed by flow cytometry and western 
analysis, indicated that the patient suffered of type II GT. The normal expression of 
platelet αvβ3 suggested that a limited availability of αIIb, but not of β3, subunit was 
involved in the etiopathogenesis of the disease. 
Sequence analysis of αIIb-cDNA from the patient revealed the presence of a C to 
T homozygous transition at position 2829 in exon 27. The predicted effect of this 
mutation is the P912L substitution in αIIb. The simultaneous homozygosis of the 
HPA-3 polymorphism, together with the impossibility of performing genetic analysis 
in the progenitors, made convenient to confirm the presence of a unique mutation at 
the DNA level. Sequencing of the corresponding genomic DNA fragment revealed 
that the mutation was present in only one allele and the patient was carrying another 
point substitution: a C1750T transition in the last codon of exon 17 that creates a 
premature termination stop codon in the 553Arg position and does not produce 
mRNA detectable in our experimental conditions of PCR amplification. This 
nonsense mutation has been previously found in heterozygous state in six unrelated 
patients: three from China, two from Japan and one from France (8). Since no 
polymorphic changes were detected at this position in 107 normal individuals from a 
Chinese province (9) the site might represent a mutational hotspot in the αIIb gene. In 
principle, the failure to detect the mutant C1750T transcript is consistent with the 
abnormal transcript being removed by nonsense-mediated decay (NMD) (16). The 
predicted mutant transcript would encode a truncated αIIb protein, 456 residues 
shorter than the normal protein, lacking the transmembrane and cytoplasmic domains, 
and a portion of the extracellular carboxyterminal fragment. However, cDNA 
sequence analysis in one of the reported cases, in which the trace amounts of the 
aberrant mRNA could be amplified due to the complete inactivation of the other αIIb 
allele (21), demonstrated a markedly reduced amount of a transcript containing a 75-
pb deletion in the 3’ boundary of exon 17 that would code for a protein carrying an in-
frame deletion of 25 residues. 
Since the C1750T mutation generates trace amounts of mRNA, the practical total 
αIIb protein detected in the patient would come from the C2829T mutant allele. The 
C2829T substitution is the first report of a mutation located in exon 27 of αIIb, that 
codes for the aminoterminal region of the light αIIb chain. Transient transfection 
experiments demonstrated that [912L]αIIb resulting from the C2829T transition can 
be expressed at the cell surface as a αIIbβ3 complex. However, the 5-fold reduction 
in the rate of expression indicates some restriction in one or more of the steps 
involved in the maturation and traffic of the complex.  
Unexpectedly, analysis of this mutation at the mRNA level revealed a significant 
increase in the number of transcripts in which exon 28 was deleted. This association 
was confirmed by exontrapping analysis of genomic DNA encompassing either the 
normal or mutated exon 27, which demonstrated that the identified mutation was 
forcing skipping of exon 28 in αIIb-mRNA. αIIb with deleted exon 28 (αIIb-28) is a 
rare alternatively spliced product of the αIIb transcript that may represent 
approximately 3% of the normally spliced form in control platelets (22). Skipping of 
exon 28 has been previously reported to increase as result of two different mutations 
in this exon. In one case the mutation creates a stop in the last codon of exon 28 and, 
at the same time, changes the consensus 5’ splice site of intron 28 forcing the exon 
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deletion in the practical totality of the transcripts (22). In contrast, the 5-bp 
duplication reported by Peretz et al. (23) abolished the normal stop codon without 
creating a new one and, like in the case reported here, a significant amount of 
nondeleted transcript was detected. In both cases, as observed in our study, the 
transcriptional rate and intracellular stability of the αIIb-28 mRNA seem not to be 
decreased with respect to the normal transcript. However, it is not expressed as a 
stable αIIbβ3 heterodimer at the surface of either platelet or transfected cells (22,24). 
According to these observations, the platelet αIIb in the present GT patient would 
come from the normal size transcript. The defective mRNA splicing promoted by the 
mutation may explain the discrepancy between the relative percents of expression of 
the mutant protein observed in platelets (less than 10% of the control) and transfected 
cells (20% of the control). Skipping of the mutant exon is a common mechanism of 
gene inactivation induced by single point mutations; nevertheless, it is less frequent 
that, like in this GT case, the mutation affected splicing of a contiguous or remote 
exon (19,25,26). The presence of weak splicing signals in the deleted exons seems to 
be a common requisite in all cases. However, in contrast to other reports (19,25,26), 
the αIIb mutation does not introduce a premature stop codon into the transcript. 
The effects of nonsense mutations on the stability and splicing of mRNA have 
been extensively studied leading to the proposal that the reading frame undergoes 
surveillance before splicing (27). However, less is known about the mechanism 
involved in altered splicing caused by misssense mutations. Since exon skipping can 
also associate to apparently silent mutations, it has been suggested that both missense 
and silent mutations must act altering cis-sequences that are important for correct 
splicing (15). Binding of serine/arginine-rich (SR) proteins to such exonic splicing 
enhancer (ESE) or silencer (ESS) sequences can promote exon definition by 
modulating recruiting of the splicing machinery. Disruption of these exonic splicing 
sequences has been proposed as the underlying mechanism in a number of mutations 
(28-30). Potential ESEs that would facilitate recognition of splice sites and prevent 
exon skipping can be identified computationally but, in many instances, it is difficult 
to predict whether a mutation will alter splicing based on sequence alone. The scores 
for individual SR protein putative recognition sites, estimated by using the available 
ESEfinder program (31), were not decreased in the mutant C2829T sequence. 
Paradoxically, the mutation was predicted to increase the score of a site for the SR 
protein SC35 from 2.418530 to 3.062970 (threshold value for the SC35 motif: 2.383). 
Although exon skipping has been coupled to disruption of SR sites (15), it has been 
shown also promoted by overexpression of the SC35 splicing factor (32,33). 
The proportion of mutations identified at the DNA level that are predicted to affect 
mRNA splicing has been often underestimated (28,34). Many recent reports show an 
increasing number of human genetic diseases due to exonic mutations that alter pre-
mRNA processing (15). In some instances, the identification of alternative transcripts 
may be the only way to explain the mechanism by which a mutation is causing a 
disease. The mutations identified in the present study are examples of genetic defects 
in which the characterization both at the genomic and RNA levels is needed in order 
to obtain a correct interpretation of its pathogenetic mechanism. The functional 
consequences of the C2829T substitution suggests that, as reported for another human 
diseases, disruption of exonic splicing elements may represent the underlying, so far 
underestimated, mechanism of gene inactivation displayed by a number of GT 
mutations. 
Finally, in the present GT patient the HPA-3a (843Ile) allele is silent at the protein 
level. HPA-3 (Ile843Ser) is a common polymorphism of platelet αIIb that gives rise to 
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posttransfusion purpura and neonatal alloimmune thrombocytopenic purpura (35). 
Thus, this case is an example in which the genotype analysis without complementary 
serological typing could have led in some circumstances to misinterpretation of 
clinical symptoms. As reported for the HPA-1 polymorphism of β3, HPA-3 seems not 
to be associated with any measurable increase of the risk for cardiovascular disease 
(36). However, in a poststroke mortality study, patients possessing the “a” allele 
demonstrated the poorest survival compared with those homozygous for the “b” allele 
(37). 
 
In summary, in the present work we have analyzed the pathogenic mechanism in a 
thrombasthenic patient carrying two mutations in exons 17 and 27 of αIIb subunit. 
The reduced αIIbβ3 in the platelet membrane seems to be the result of unstable αIIb 
mutant transcripts, enhanced expression of aberrant αIIb-28 transcripts, and inefficient 
processing of [912Leu]αIIb protein. The detected binding of labeled fibrinogen 
suggests that the expressed mutant protein might be functional but not sufficient to 
support platelet aggregation. 
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Legends to the Figures 
Fig. 1. Flow cytometry analysis of platelet surface αΙΙbβ3  fibrinogen binding to 
platelets 
(A) Surface expression of αIIbβ3 and GPIbIX. Washed platelets were incubated 
with specific mAbs against either αIIb (2BC1), β3 (H1AG11), GPIbα (AK2), or 
GPIX (SZ1), as described in Methods. The negative control represents the 
fluorescence of platelets incubated only with the second FITC-labeled antibody. The 
mean channel of fluorescence is indicated in each panel. (B) Binding of soluble 
fibrinogen to platelets from the thrombasthenic patient and a control. Platelets were 
processed as described in Methods and preincubated for 5 min with the indicated 
activator before FITC-Fg addition. Numbers correspond to the values of fluorescence 
calculated as a product of the percent of gated positive cells and the value of mean 
channel of fluorescence. 
 
Fig. 2. Analysis of platelet αIIb, β3 and αvβ3 content 
(A) Immunoblot analysis of αIIb and β3. Platelet lysates were resolved on SDS-
7.5% polyacrylamide gels under non-reduced conditions and transferred to PVDF 
membranes. Immunoblotting with 1 µg/mL of the mixed monoclonal antibodies was 
performed as described in Materials and methods. (B) The analysis was repeated three 
times using different protein concentrations and data were quantified by densitometry. 
(C) Analysis of platelet αvβ3 content. Immunoprecipitation of αvβ3 and western 
blotting analysis of the immunoprecipitates were performed as described under 
Methods. 
 
Fig. 3. Identification of mutations in the αIIb gene 
(A) Direct sequencing of antisense strand of the 3’ overlapping RT-PCR product 
showing an homozygous G to A substitution that changes Pro to Leu in the GT 
patient. (B) Sequence analysis of genomic DNA fragments revealed the heterozygous 
status of the missense mutation found in the cDNA (lower panel), and the presence of 
nonsense Arg/STOP mutation as result of a C/T transition in the last codon of exon 17 
(upper panel). 
 
Fig. 4. Exontrap analysis of αIIb genomic fragments 
Fragments of normal and mutant genomic DNA of αIIb were cloned into the 
expression vector pET01, in which the intron containing the multicloning site is 
framed by the 5’ donor and 3’ acceptor splice sites. CHO cells were transiently 
transfected with the normal or mutated αIIb construct and the splicing patterns 
deduced by agarose gel and sequence analysis of the reverse transcriptase-PCR 
products, as described in Methods 
 
Fig. 5. Surface expression of αIIbβ3 in transiently transfected CHO-β3 cells 
CHO cells stably expressing β3 subunit were transfected with pcDNA3 plasmid 
containing either normal or mutated αIIb cDNAs. 48 hours after transfection the 
surface expression of αIIbβ3 complexes was determined by flow cytometry using the 
2BC1 mAb. The fluorescence values were calculated as a product of the percent of 
gated positive cells and the value of the mean channel of fluorescence. Data are 
representative of three independent transfection experiments. 
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